# the Efficacy and Safety of CLAE in R/R T-ALL/LBL

> **NCT04679506** · — · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

## Interventions

- **DRUG:** Cladribine

## Key facts

- **NCT ID:** NCT04679506
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12
- **Primary completion:** 2021-12
- **Final completion:** 2023-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679506, "the Efficacy and Safety of CLAE in R/R T-ALL/LBL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04679506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*